Drugmaker Lupin Ltd. on Tuesday said it has launched a generic medication for the treatment of postoperative inflammation in the U.S. market.
The company has launched Bromfenac Ophthalmic Solution (0.07%), after having received approval from the U.S. Food and Drug Administration (USFDA), the Mumbai-based firm said in a regulatory filing.
The company is the exclusive first-to-file for this product and is eligible for 180-day exclusivity, it added.
Bromfenac Ophthalmic Solution, 0.07%, is the generic equivalent of Bausch & Lomb Inc's Prolensa ophthalmic solution, Lupin said.
It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
As per the IQVIA MAT data, Bromfenac ophthalmic solution had estimated annual sales of $182 million in the U.S.
RECOMMENDED FOR YOU
FIDE World Cup To Be Held In Goa From Oct. 30 To Nov. 27
Aug 26, 2025
Motoverse 2025: Royal Enfield's Popular Festival Is Back In Goa — Check Dates, Tickets
Aug 20, 2025
Goa: FIR Against Cabbie, Uber For ‘Illegal’ Operations At Mopa Airport
Aug 20, 2025
Lupin Q1 Review: Dolat Capital Maintains 'Add', But Cuts Target Price — Here's Why
Aug 07, 2025
POPULAR